INTRODUCTION Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year.
New York, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Sterile Small Molecule Fill / Finish Services by Fill / Finish Technique, Type of Packaging, Type of Dosage Form and Geography : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p06020736/?utm_source=GNW
Given that the demand for small molecule drugs is still on the rise, the importance of contract manufacturing and third party services is also increasing in the pharmaceutical industry. Sterile fill / finish is considered among the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill / finish operations are not only essential for ensuring end user safety, but also maintaining pharmacological efficacy and product quality. As small molecule APIs are gradually becoming more complex, the demand for appropriate aseptic fill / finish processes is growing.
Given the high cost of specialized equipment and the affiliated expertise required for aseptic fill / finish operations, it is difficult for drug developer companies with limited finances and capacity constraints to meet clinical / commercial scale demands. This has led many of the smaller players in the industry and certain pharma giants, as well, to outsource various aspects of their production processes, including fill / finish, to contract service providers. Currently, over 130 companies are actively providing sterile fill / finish services for small molecules. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. We believe that this trend is likely to persist in the foreseen future, as well. Overall, the contract services market for fill / finish of small molecule drugs is anticipated to witness steady growth, till 2030.
SCOPE OF THE REPORT
The ‘Sterile Small Molecule Fill / Finish Services Market, 2020-2030’ report features an extensive study of the current market landscape and the future potential of sterile fill / finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed review of the overall landscape of contract fill / finish services market for small molecules, featuring a list of service providers and detailed analysis based on a number of relevant parameters, including developer information (year of establishment, company size and location of headquarters), scale of operation (preclinical, clinical and commercial), type of fill / finish technique (aseptic filling / terminal sterilization and blow-fill-seal), dosage forms handled (liquid, lyophilized, micelles / liposomes and powder), and types of primary packaging containers handled (vials / ampoules, pre-filled syringes / syringes / cartridges and bottles / others).
- A region-wise, company competitiveness analysis, highlighting prominent fill / finish service providers, based on supplier strength (considering experience of the service provider) and portfolio strength (considering the number of dosage forms handled, number of containers for which fill / finish service is being provided, number of fill / finish techniques adopted and scale of operation).
- Elaborate profiles of key players across key geographies (North America, Europe and Asia-Pacific), which were shortlisted based on our proprietary company competitiveness analysis. Each profile provides an overview of the company, details related to their fill / finish service portfolio, financial performance (if available), and an informed future outlook.
- A detailed analysis of the expansions undertaken (since 2016) by various service providers, based on a number of parameters, including year of expansion, type of expansion (capacity expansion, capability expansion, new facility, geographical consolidation and geographical expansion), geographical location of facility and most active players (in terms of number of instances).
- An estimate of the global, contract fill / finish capacity, by taking into consideration the capacities of various fill / finish service providers (as available on respective company websites), collected via secondary research. The study examines the distribution of number of packaging units and volume of small molecules filled, across various types of packaging (ampoules, bottles, pre-filled syringes and vials), based on the size of the company / organization (small-sized, mid-sized and large / very large) and geography (North America, Europe and Asia Pacific).
- A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes; the study provides a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
- A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations; the study provides a list of suppliers providing the ready-to-use components.
One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for sterile small molecule service providers. Based on parameters, such as such as growth of the overall pharmaceutical market, the cost associated with fill / finish operation and outsourcing trends related to these operations, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of
[A] fill / finish technique (aseptic filling, terminal sterilization and blow-fill-seal)
[B] type of packaging (ampoules, bottles, pre-filled syringes and vials)
[C] type of dosage form (liquid, lyophilized and others)
[D] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Australia, India, South Korea and rest of the Asia), Middle East and North Africa and Latin America).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views
While the focus has been on forecasting the market till 2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the sterile small molecule service providers market in the mid to long term.
Chapter 3 provides a general introduction to pharmaceutical contract manufacturing industry. The chapter lays emphasis on the important sterile fill / finish techniques that are being adopted by the industry for packaging of small molecule drugs. It includes information on key factors that need to be considered during the selection of fill / finish service providers, as well as the advantages and associated risks or challenges related to outsourcing fill / finish operations.
Chapter 4 provides an overview of the overall sterile small molecule fill / finish contract services landscape. It includes information related to 130 contract service providers that are currently active in this domain. It features in-depth analyses of the market, based on a number of relevant parameters, such as year of establishment, company size and geographical location of the service providers, location of fill / finish facilities, information on various fill / finish techniques (aseptic filling, terminal sterilization and blow-fill-seal), types of dosage form (liquid, lyophilized, micelles / liposomes and powder / others), types of packaging (ampoules / vials, cartridges / pre-filled syringes / syringes and bottles / others) and scale of operation (preclinical, clinical and commercial).
Chapter 5 provides an insightful competitiveness analysis of the service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service portfolio strength (which takes into account the number of dosage forms handled, number of containers for which fill / finish service is being provided, number of fill / finish techniques adopted and scale of operation).
Chapter 6 features detailed profiles of some of the key players that are active in the sterile small molecule contract manufacturing domain. Each profile presents a brief overview of the company, its fill / finish service portfolio, financial information (if available), recent developments and an informed future outlook.
Chapter 7 presents detailed analyses of the expansions that have taken place since 2016. These have been analyzed on various parameters, including year of expansion, purpose of expansion (capacity expansion, capability expansion, new facility, geographical consolidation and geographical expansion), geographical location of the facility, and also highlights the most active players (in terms of number of instances) in the domain.
Chapter 8 features a comprehensive analysis of the global sterile small molecule fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The study examines the distribution of global sterile small molecule fill / finish capacity of the industry in terms of number of packaging units, type of packaging (ampoules, bottles, pre-filled syringes and vials), size of the manufacturer (small-sized, mid-sized and large / very large) and geography (North America, Europe and Asia-Pacific).
Chapter 9 presents a comprehensive market forecast analysis, highlighting the likely growth of sterile small molecules’ fill / finish services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of fill / finish technique (aseptic filling, terminal sterilization and blow-fill-seal), type of packaging (ampoules, bottles, pre-filled syringes and vials), type of dosage form (liquid, lyophilized and other dosage form), and key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia (Australia, India, South Korea and rest of the Asia), Middle East and North Africa and Latin America).
Chapter 10 is a case study focused on use of robotic systems in fill / finish operations. It provides a list of equipment used for fill / finish, highlighting the role of robotics in various manufacturing operations. It also includes list of companies providing robots for use in pharmaceutical production processes.
Chapter 11 is a case study which describes the use of ready-to-use packaging components in the aseptic fill / finish operations. It also provides a list of suppliers providing ready-to-use components.
Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.
Read the full report: https://www.reportlinker.com/p06020736/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001